Abstract
Denosumab, a human monoclonal antibody that inhibits osteoclastic-medicated bone resorption by binding to RANK ligand and preventing activation of the receptor RANK on osteoclasts and their precursors. Over 10 years, denosumab significantly reduced ver-tebral, nonvertebral, and hip fracture risk compared with placebo, and had an excellent safety profile.
Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. In ostmenopausal women with osteo-porosis, treatment was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months.
Treatment with biologic drugs is associated with the decrease in bone loss. Studies with anti-TNF blocking agents show decrease in bone loss and BMD, and a better profile of bone markers.
There are unmet needs for studies regarding their actions on the risk of bone fractures.